

February 13, 2026

To, BSE Limited, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 Ref: Company Scrip Code: 532834	To, Listing Department, National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Ref: Symbol: CAMLINFINE Series: EQ
--	---

Sub: Outcome of the Board Meeting: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“Listing Regulations”) (read with Schedule III).

Dear Sir/Madam,

This has reference to our intimation dated February 5, 2026.

This is to inform you that the Board of Directors of the Company, at its meeting held today i.e. on Friday, February 13, 2026, inter alia, approved the un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2025. A copy of the said Results along with the Limited Review Reports issued by the Statutory Auditors are enclosed herewith as Annexure 1. The said Results shall be published in newspapers as per the Listing Regulations.

The above information is also available on the Company’s Website (<https://www.camlinfs.com/>).

The Board meeting commenced at 01:30 p.m. (IST) and concluded at 03:45 p.m. (IST).

This is for your information and record please.

Encl.: a/a.

Thanking You,

For Camlin Fine Sciences Limited

Rahul Sawale
Company Secretary
& VP - Legal



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLCO75361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

CAMLIN FINE SCIENCES LIMITED
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

	PARTICULARS	STANDALONE												CONSOLIDATED											
		QUARTER ENDED			NINE MONTHS ENDED			YEAR ENDED			QUARTER ENDED			NINE MONTHS ENDED			YEAR ENDED								
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2024 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)								
1	Revenue from operations	21,892.16	24,404.19	20,507.10	65,440.17	61,389.50	88,649.13	45,719.67	293.55	45,982.69	43,102.86	133.62	739.75	134,057.56	122,906.38	166,652.96									
2	Other income	576.69	1,019.36	681.73	1,964.92	1,167.87	2,061.53	458.82	46,013.22	46,441.51	43,235.98	46,441.51	134,797.31	123,392.39	168,097.92										
3	Total income	22,468.85	25,423.55	21,188.83	67,405.09	62,557.37	90,710.66	46,013.22	91,495.81	92,423.20	86,338.84	89,884.33	149,294.62	257,450.00	236,303.77	334,750.88									
4	Expenses	11,068.08	11,440.12	10,644.57	32,414.26	38,919.60	53,922.47	26,766.44	20,302.26	20,302.26	17,104.76	70,254.18	59,139.59	78,626.18	78,626.18										
	Cost of materials consumed	80.58	37.11	48.25	1,647.08	1,637.08	1,995.32	1,373.19	3,191.85	3,191.85	4,539.94	6,306.38	11,517.06	11,753.19											
	Purchase of stock in trade	128.83	1,936.54	(563.39)	2,360.34	(7,165.32)	(7,491.39)	(3,338.10)	577.49	(234.01)	(3,240.51)	(3,240.51)	(7,260.59)	(5,453.54)											
	Changes in inventories of finished goods/WIP/stock in trade	1,992.86	1,935.57	1,718.20	5,790.50	5,359.10	7,248.10	6,376.36	6,029.31	4,791.79	18,362.66	14,216.46	19,229.13	19,229.13											
	Employee benefits expense	1,486.33	1,872.91	1,714.51	4,493.63	4,868.03	6,611.93	1,832.90	1,890.82	3,407.08	5,306.43	8,377.23	9,988.22	9,988.22											
	Finance costs	1,351.49	1,347.41	1,326.22	4,039.22	3,939.18	5,252.66	1,672.77	1,882.73	1,447.99	5,247.53	4,545.27	6,386.89	6,386.89											
	Depreciation and amortisation expense	6,721.80	7,234.91	7,019.94	20,522.14	18,905.80	26,214.41	12,338.56	11,940.52	11,123.89	30,423.32	30,423.32	41,686.45	41,686.45											
	Other expenses	22,829.97	25,804.57	21,908.30	69,784.88	66,463.44	93,453.50	47,022.12	46,414.98	42,181.44	136,995.18	120,958.36	162,213.52	162,213.52											
5	Profit / (Loss) before exceptional items and share of profit / (loss) of associate (3-4)	(661.12)	(381.02)	(715.47)	(2,379.79)	(3,906.07)	(2,742.84)	1,008.90	26.53	26.53	1,054.54	(1,497.87)	2,434.03	5,884.40											
6	Exceptional items (Refer Note 7)	1,365.81	-	-	1,365.81	9,626.66	9,600.21	1,751.13	-	-	-	1,751.13	422.12	981.52											
7	Profit / (Loss) before share of profit / (loss) of associate (5-6)	(1,726.93)	(381.02)	(715.47)	(3,745.60)	(13,532.73)	(12,343.05)	(2,760.03)	26.53	26.53	1,054.54	(3,249.00)	2,011.91	4,902.88											
8	Share of profit / (loss) of associate	-	-	-	-	-	-	(25.29)	(35.76)	(194.89)	27.92	(134.39)	44.22												
9	Profit / (Loss) before tax from continuing operations (7-8)	(1,726.93)	(381.02)	(715.47)	(3,745.60)	(13,532.73)	(12,343.05)	(2,785.42)	(9.23)	(9.23)	869.65	(3,221.08)	1,877.52	4,947.10											
10	Tax Expenses	-	-	-	-	165.97	165.97	441.24	561.14	561.14	432.28	1,599.97	2,813.64	4,212.81											
	- Current tax	(427.27)	(17.11)	(156.75)	(1,013.93)	(4,305.81)	(4,877.97)	(436.73)	30.07	282.14	(1,005.24)	(3,602.19)	(4,206.16)												
	- Deferred tax	(427.27)	(17.11)	(156.75)	(1,013.93)	(4,339.84)	(4,712.00)	4.52	591.21	600.44	155.23	(3,815.81)	2,666.07	4,940.45											
11	Profit / (Loss) from continuing operations for the period (9-10)	(1,299.66)	(363.91)	(562.22)	(2,731.67)	(9,192.89)	(7,631.05)	(2,789.94)	(600.44)	(600.44)	155.23	(2,457.61)	(1,848.91)	(30,752.39)											
12	Discontinued operations	-	-	-	-	-	-	(920.35)	(894.56)	(894.56)	(902.39)	(2,457.61)	(18,489.01)	(20,752.39)											
	Profit / (Loss) from discontinued operation before tax	-	-	-	-	-	-	(920.35)	(894.56)	(894.56)	(902.39)	(2,457.61)	(18,489.01)	(20,752.39)											
	Tax expense of discontinued operations	-	-	-	-	-	-	-	-	-	-	-	-	-											
13	Profit / (Loss) from operations for the period (11-12)	(1,299.66)	(363.91)	(562.22)	(2,731.67)	(9,192.89)	(7,631.05)	(2,789.94)	(600.44)	(600.44)	155.23	(2,457.61)	(18,489.01)	(30,752.39)											
14	Other comprehensive income	19.67	(11.66)	8.60	(81.44)	(30.76)	(12.26)	19.67	(116.66)	(116.66)	8.60	(81.44)	(30.76)	(11.80)											
A	Items that will not be reclassified to profit or loss	(6.87)	40.76	(3.00)	28.46	10.75	4.28	(6.87)	40.76	40.76	(3.00)	28.46	10.75	4.28											
	(i) Remeasurements of defined benefit plans	-	-	-	-	-	-	-	-	-	-	-	-	-											
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-	-											
B	Items that will be reclassified to profit or loss	26.54	(52.42)	11.60	(109.90)	(41.51)	(16.54)	26.54	(52.42)	(52.42)	11.60	(109.90)	(41.51)	(16.54)											
	(i) Exchange differences on translating the financial statements of foreign operations	-	-	-	-	-	-	-	-	-	-	-	-	-											
	(ii) The effective portion of gain or loss on hedging instruments in a cash flow hedge	26.54	(52.42)	11.60	(109.90)	(41.51)	(16.54)	26.54	(52.42)	(52.42)	11.60	(109.90)	(41.51)	(16.54)											
	(iii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-	-											
15	Other comprehensive income	32.47	(45.30)	(232.12)	(370.36)	(248.35)	(54.04)	437.88	(97.82)	(97.82)	1,210.64	1,532.92	(1,802.96)	(1,223.49)											
	Total comprehensive income for the period (13-14)	(1,267.19)	(789.21)	(794.84)	(3,102.03)	(9,441.24)	(7,685.09)	(3,272.41)	(1,592.82)	(1,592.82)	(1,957.80)	(4,740.50)	(17,625.90)	(17,625.90)											



**ASHISH
SUBHASH
DANDEKAR**

Digitally signed by ASHISH SUBHASH DANDEKAR
 DN: cn=, st=Maharashtra,
 2.5.4.20=ashish@camlin.com, postalCode=400050,
 o=Camlin Fine Sciences Ltd., postalCode=400050,
 street=Flat No. 9J Concorde Apartment 9th Floor Bullock
 Road Bandra West Mumbai,
 pseudonymid=7a54dce55143bbd47958810eaf5f92,
 title=Signer
 serialNumber=2d66c925e71aa302015830663043413b
 0d0c1875c416a02d8658a25085, o=Personal,
 cn=ASHISH SUBHASH DANDEKAR
 Date: 2026.02.13 16:05:05 +05'30'

Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
 CIN: L74100MH1993PLCO75361

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfs.com

www.camlinfs.com



For Camlin Fine Sciences Limited

Ashish S. Danekar
Chairman & Managing Director
DIN: 01077379

**ASHISH
SUBHA
SH
DANDE
KAR**

Digitally signed by ASHISH
SUBHASH DANDEKAR
DN: c=N, st=Maharashtra,
2.5.4.20=a4605618a40c16a58
78aa5480790d46625a950fb
a503b19e012abbd75a,
postalCode=400050,
street=Flat No 5 Concord
Apartment 9th Floor Bullock
Road Bandra West Mumbai,
pgidonym=07444ee05143
bd47958810ea4592,
title=2999,
serialNumber=2065c925e71a
a302015830d63040413b0a0
c18795c416a02b6658a25085,
o=Personal, ou=ASHISH
SUBHASH DANDEKAR
Date: 2026.02.13 16:05:58
+05'30

3 Finance costs of continuing operation include foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE						CONSOLIDATED					
	QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED	QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED		
	31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.03.2025 (Audited)	31.12.2024 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.03.2025 (Audited)		
Exchange gain	218.43	666.45	431.46	874.61	543.12	370.29	370.29	1,782.11	405.79	2,943.71		
Exchange loss	(218.43)	(666.45)	(431.46)	(874.61)	(543.12)	(370.29)	(370.29)	(1,782.11)	(405.79)	(2,943.71)		
Total Exchange gain / (loss)	-	-	-	-	-	57.04	-	-	-	-		

4 During the quarter ended December 31, 2025, the Company has issued and allotted under the CFS Employees Stock Option Plan 2020 (ESOP-2020). No employee stock options have lapsed under the respective ESOP-2018 and ESOP-2020 schemes during the quarter ended December 31, 2025. Further, 16,23,000 options were granted to eligible employees under Camlin Fine Sciences Limited Employees Stock Option Plan, 2021.

5 During the quarter, the Company has made a further investment of Rs.145.97 lakh in addition to Rs. 345 lakh made in the previous quarter to acquire 49% equity shares in CleanMax Sundarban Private Limited, a Special Purpose Vehicle (SPV) formed jointly with CleanMax Enviro Energy Solutions Private Limited, for setting up of 3.3 MW wind-solar hybrid power plant at Dabai, Gujarat. As per the Shareholder's Agreement, the Company does not have any significant influence over the SPV. Consequently, the SPV has not been considered as an associate and accordingly, the consolidated financial results do not include the Company's share of results of the SPV.

6 On February 24, 2025, the Company and certain significant shareholders of Vinpai S.A. ("Vinpai"), including its founders entered into a Share Purchase Agreement for acquisition by the Company of 2,723,316 ordinary shares of Vinpai at Euro 3.60 per ordinary share. The consideration payable for the acquisition as per SVA was determined at Euro 9,803,937.60 equivalent to Rs. 10,170.60 lakh. On November 30, 2025, the said consideration was discharged by issue of 4,106,181 fresh equity shares of the Company having a face value of Rs. 1 each and securities premium of Rs. 246.69 per share. Further, the Company invested Euro 3.90 million in Vinpai through subscription to 3,300 listed secured convertible bonds having a subscription price of € 1,000 per bond issued by Vinpai on February 24, 2025. These bonds matured on December 31, 2025, and were converted into 1,100,000 new ordinary shares of Euro 3 per ordinary share of Vinpai at its fair value of INR 4,157.17 lakh, pursuant to the issue of shares and conversion of bonds by the Company, the Company now holds 3,823,316 shares of Vinpai representing 83.82% of Vinpai's outstanding share capital. The consolidated financial statements of the Group include the audited results of Vinpai for the period December 1, 2025, to December 31, 2025.

7 Note on Exceptional Items
On November 21, 2025, the Government of India notified four Labour Codes (the Code on Wages 2019, the Code on Social Security 2020, the Industrial Relations Code 2020, and the Occupational Safety, Health and Working Conditions Code, 2020) consolidating 29 existing labour laws (collectively 'new Labour Codes'). In accordance with the new Labour Codes, the Company has currently estimated the incremental impact on retirement benefits consisting of gratuity and leave encashment to be Rs. 222.17 lakh. Considering the materiality and regulatory driven non-recurring nature of this development, it has been presented under "Exceptional Items" in the standalone / consolidated financials results. The Company continues to monitor the finalization of Central / State Rules and clarifications from the Government on other aspects of the Labour Codes and would provide appropriate accounting effect as and when such clarifications are issued / rules are notified.
Accordingly, the exceptional expense items, recognised in the Profit & Loss in the current quarter includes:

- 1. In Standalone Financial Results -
- i) Provision for doubtful loan/advance of Rs. 1,151.20 lakh
- ii) Impact of the New Labour Codes on retirement benefits of Rs. 222.17 lakh
- iii) Provision for doubtful loan/advance of Rs. 1,151.20 lakh
- iv) Acquisition related cost of Vinpai Rs. 369.10 lakh
- v) Impact of the New Labour Codes on retirement benefits of Rs. 222.17 lakh

8 a) On January 15, 2026, the Board of Statutory Auditors of wholly owned subsidiary CFS Europe Spa, have filed a petition with the local judicial authority for liquidation of the subsidiary as in their opinion, the entire operations of CFS Europe are commercially unviable and that it is a fit case for liquidation. The Board of CFS Europe on January 28, 2026 and subsequently the Board of the Company on February 13, 2026 have resolved to pursue the proceedings as per the directions of the local judicial authority. The hearing of the petition is slated on February 26, 2026. The finality on the status of liquidation will be based on the final directions issued by the local judicial authority. Pursuant to the above, the Group continues to classify the operations of the Diphenol facility of the subsidiary as discontinued operations and the operations of the Blending facility as continued operations. No further impairment provision for the assets of CFS Europe is required based on the management estimate of the fair value thereof.

b) The operations of the Vanillin manufacturing facility of CFS Wanglong Flavors (Ningbo) Co. Ltd., China (a subsidiary), had ceased its manufacturing activities with effect from February 19, 2021, since its operations were considered economically unviable. The operations continue to be classified as discontinued operations.

9 On February 7, 2026, a major fire incident occurred at one of the two Blending units of CFS Do Brasil Industria, Comercio, Importacao e Exportacao de Alimentos LTDA, a wholly owned subsidiary. This has led to significant damage to inventories and plant and machinery kept at that blending unit which had carrying value in the books of approximately Rs. 3,300 lakh. Though, the operations at the unit remain suspended as on the date, the subsidiary is making alternative arrangement for the necessary funding and manufacturing activity at the other blending unit to continue its service to the customers. This incident has been reported to the insurer and is currently under necessary procedure for loss assessment. The final financial impact arising from this incident is not determinable at present. As this event occurred post the reporting period and is of a non-adjusting nature, no accounting effect thereof is given in the results for the current quarter ended December 31, 2025.

10 The Company's operations constitute a single business segment i.e. Specialty Chemicals.

Place: Mumbai
Date: February 13, 2026

Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfs.com

www.camlinfs.com

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

REVIEW REPORT

To The Board of Directors
Camlin Fine Sciences Limited

LIMITED REVIEW REPORT

- 1) We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Camlin Fine Sciences Limited** (“the Company”) for the quarter and nine months ended December 31, 2025, together with the notes thereon, (“the Statement”) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Listing Regulations”). This Statement, which is the responsibility of the Company’s Management, has been reviewed by the Audit Committee and approved by the Board of Directors, at their respective meetings held on February 13, 2026, and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’ (“Ind AS 34”) prescribed under Section 133 of the Companies Act, 2013, (“the Act”) read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 2) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Kalyaniwalla & Mistry LLP**

Chartered Accountants

Firm Registration No.: 104607W/W100166

ANIL ARVIND Digitally signed by ANIL
ARVIND KULKARNI
Date: 2026.02.13 16:14:20
KULKARNI +05'30'

Anil A. Kulkarni

Partner

Membership No.: 047576

UDIN: 26047576OAJZHT9015

Place: Pune

Date: February 13, 2026

LLP IN : AAH - 3437

3RD FLOOR, PRO1 BUSINESS CENTER, SENAPATI BAPAT ROAD, PUNE – 411 016

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (20) 2 5 6 7 1 5 1, FAX: (91) (20) 2567 6427

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

REVIEW REPORT

To The Board of Directors
Camlin Fine Sciences Limited

LIMITED REVIEW REPORT

- 1) We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Camlin Fine Sciences Limited** ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of net profit / (loss) after tax and total comprehensive income of an associate of a step down subsidiary (refer paragraph 3 below) for the quarter and nine months ended December 31, 2025 together with the notes thereon ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ("the Listing Regulations"). This Statement, which is the responsibility of the Parent's Management has been reviewed by the Parent's Audit Committee and approved by Parent's Board of Directors, at their respective meetings held on February 13, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, ("the Act"), read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 2) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

- 3) The Statement includes the results of the following subsidiaries / step down subsidiaries / associate:

Sr. No.	Name of the Entity	Relationship
Incorporated In India		
i.	Chemolutions Chemicals Ltd.	Subsidiary
ii.	AlgalR Nutra Pharms Private Limited	Subsidiary
Incorporated Outside India		
iii.	CFS North America LLC	Wholly owned subsidiary
iv.	CFS Do Brasil Indústria, Comércio, Importação e Exportação De Aditivos Alimentícios LTDA	Wholly owned subsidiary
v.	Solentus North America Inc	Wholly owned subsidiary
vi.	CFS Europe S.P.A	Wholly owned subsidiary

LLP IN : AAH - 3437

3RD FLOOR, PRO1 BUSINESS CENTER, SENAPATI BAPAT ROAD, PUNE – 411 016

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (20) 2 5 6 7 1 5 1, FAX: (91) (20) 2567 6427

Sr. No.	Name of the Entity	Relationship
vii.	Dresen Quimica S.A.P.I de C.V.	Wholly owned subsidiary
viii.	Industrias Petrotec De Mexico S.A. de C.V.	Step down subsidiary
ix.	Nuvel, S.A.C.	Step down subsidiary
x.	Britec, S.A.	Step down subsidiary
xi.	Inovel, S.A.S	Step down subsidiary
xii.	Grinel, S.R.L	Step down subsidiary
xiii.	CFS Wanglong Flavors (Ningbo) Co. Ltd.	Subsidiary
xiv.	CFS Pahang Asia Pte. Ltd (Struck off w.e.f. November 4, 2025).	Subsidiary
xv.	CFS Argentina S.A.	Step down subsidiary
xvi.	CFS Chile De SPA	Step down subsidiary
xvii.	CFS PP (M) SDN. BHD	Subsidiary
xviii.	Vitafor Invest NV, Belgium	Step down subsidiary
xix.	Vitafor NV,	Step down subsidiary
xx.	Addi-Tech NV	Step down subsidiary
xxi.	Vitafor China Ltd.	Step down subsidiary
xxii.	Vial SARL	Associate of a step down subsidiary
xxiii.	Vinpai S. A. (w.e.f. November 30, 2025)	Subsidiary
xxiv.	Based Algae & Plants, France (w.e.f. November 30, 2025)	Step down subsidiary

- 4) Based on our review conducted and procedures performed as stated in paragraph 2 above, and based on the consideration of the review reports of the other auditors referred to in paragraph 6(A) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 5) **Emphasis of Matter:**

We draw attention to Note 9 to the Statement wherein it has been stated that, on February 7, 2026, a major fire incident occurred at one of the two Blending units of CFS Do Brasil Industria, Comercio, Importacao e exportacao de Aditivos Alimenticios LTDA, a wholly owned subsidiary of the Parent. The operations at the unit remain suspended as on date. This incident has been reported to the insurer and is currently under necessary procedure for loss assessment. The financial impact arising from this incident is not determinable at present.

In the opinion of the Management of the Company, this event has been considered as a non-adjusting event as per Ind AS 10, "Events after the Reporting Period".

Our conclusion on the Statement is not modified in respect of the above matter.

6) Other Matters:

- A. We did not review the interim financial results of 15 subsidiaries incorporated outside India and 2 subsidiaries in India included in the Statement, whose interim financial results reflect Group's share of total revenues (before consolidation adjustments) of Rs.30,540.53 Lakh and Rs.89,863.68 Lakh for the quarter and for the nine months ended December 31, 2025, respectively, Group's share of total net loss after tax (before consolidation adjustments) of Rs.4,720.95 Lakh and Rs.6,112.14 Lakh and total comprehensive income (before consolidation adjustments) of Rs. (6,298.16) Lakh and Rs (3,971.56) Lakh for the quarter and nine months ended December 31, 2025, respectively.

These interim financial results of the subsidiaries as mentioned in this paragraph have been reviewed by other auditors whose reports have been furnished to us by the Parent's Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 2 above.

In respect of the subsidiaries located outside India, the interim financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's Management has converted the interim financial results of these subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India (Indian Accounting Standards "Ind AS"). We have reviewed the conversion adjustments made by the Parent's Management.

- B. The Statement includes interim financial results of 6 subsidiaries incorporated outside India which have not been reviewed, whose interim financial results reflect Group's share of total revenues (before consolidation adjustments) of Rs.590.12 Lakh and Rs.1,124.98 Lakh for the quarter and nine months ended December 31, 2025, respectively, Group's share of total net loss after tax (before consolidation adjustments) of Rs.206.33 Lakh and Rs.1,219.06 Lakh and total comprehensive income (before consolidation adjustments) of Rs.(145.00) Lakh and Rs.(734.61) Lakh for the quarter and nine months ended December 31, 2025, respectively.

The Statement also includes the Group's share of net profit/ (loss) after tax (before consolidation adjustments) and total comprehensive income (before consolidation adjustments) of Rs.(25.39) Lakh and Rs.27.92 Lakh for the quarter and nine months ended December 31, 2025 respectively as considered in the consolidated unaudited financial results, in respect of an associate of a step down subsidiary, located outside India, which have not been reviewed.

These interim financial results have been furnished to us by the Parent's Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate of a step-down subsidiary, is based solely on such interim financial results certified by management. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matters.

For **Kalyaniwalla & Mistry LLP**
Chartered Accountants
Firm Registration No.: 104607W/W100166

ANIL ARVIND Digitally signed by ANIL
KULKARNI ARVIND KULKARNI
Date: 2026.02.13
16:15:11 +05'30'

Anil A. Kulkarni
Partner
Membership No.: 047576
UDIN: 26047576XXFIFY6113
Place: Pune
Date: February 13, 2026

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTH ENDED DECEMBER 31, 2025
(Rs. in Lakh, except per share data)

No.	PARTICULARS	STANDALONE						CONSOLIDATED					
		QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED		QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED	
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.03.2025 (Audited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
1	Total Income from Operations	21,892.16	21,404.19	20,307.10	65,440.17	61,389.51	88,019.13	45,719.67	45,982.69	13,102.36	13,057.56	122,996.38	
2	Net Profit / (Loss) for the period from continuing operations (before tax and exceptional items)	(361.12)	(381.02)	(719.47)	(2,379.79)	(3,986.07)	(2,712.84)	(1,031.29)	(9.23)	869.65	(1,469.95)	2,299.64	
3	Net Profit / (Loss) for the period before tax from continuing operations (after exceptional items)	(1,726.93)	(381.02)	(719.47)	(3,745.60)	(13,332.73)	(12,343.05)	(2,783.12)	(9.23)	869.65	(3,221.08)	1,877.57	
4	Total Non-operating Profit / (Loss) for the period after tax (after exceptional items)	(1,299.66)	(363.93)	(567.72)	(2,731.67)	(9,339.89)	(7,631.05)	(3,716.29)	(1,495.03)	(737.16)	(6,273.42)	(15,811.94)	
5	Net Profit / Loss for the period after tax and non-controlling interests (after exceptional items)	(1,267.19)	(789.21)	(794.84)	(3,102.03)	(9,441.24)	(7,685.08)	(3,273.41)	(1,438.49)	(413.64)	(6,057.48)	(13,904.59)	
6	Total Comprehensive Income for the period	1,920.92	1,879.80	1,674.95	1,920.92	1,674.95	1,879.21	1,920.92	1,879.80	1,674.95	1,920.92	(17,035.13)	
7	Equity Share Capital											1,879.21	
8	Other Equity											88,288.99	
9	Earnings per share (of Rs. / each) (not annualised)	(0.69)	(0.19)	(0.33)	(1.45)	(5.40)	(4.41)	(1.91)	(0.77)	(0.24)	(3.21)	(8.12)	
	Basic Rs.											(8.12)	
	Diluted Rs.											(8.03)	

The above information is an extract of the detailed format of unaudited results for the quarter ended December 31, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited results for the quarter December 31, 2025 are available on the Company's website at www.camlinfsc.com and the Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com.



For Camlin Fine Sciences Limited

Ashish S. Dandekar
Chairman & Managing Director
DIN: 01077379

**ASHISH
SUBHAS
H
DANDEKAR**

Digitally signed by ASHISH SUBHASH DANDEKAR
DN: cn=IN, st=Maharashtra, 2.5.4.20=4605181846301655878a8454807a90f4652a95e0ba503d b19e012abb075a, postalCode=400050, street=Flat No 9 Concord Apartment 9th Floor Bullock Road Bandra West Mumbai, pseudonym=754d4ce45143bd 647958810a45f92, title=2699, serialNumber=2d66c025671aa30 2f01583063043413786d0c187f3 c0168a028658a2905, o=PERSONAL, ou=ASHISH SUBHASH DANDEKAR
Date: 2026.02.13 16:06:31 +05'30'

Place: Mumbai
Date: February 13, 2026

Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfsc.com

www.camlinfsc.com